title: [Effects of telmisartan on IKCa1 potassium channel after T-lymphocyte activation and proliferation in peripheral blood of hypertensive patients in Xinjiang Kazakh].
abstract: OBJECTIVE
  To explore the effects of Telmisartan on IKCa1 potassium channel after T-lymphocyte activation and proliferation in peripheral blood of hypertensive patients in Xinjiang Kazakh.
  
  
  METHODS
  Peripheral blood T cells in vitro culture were isolated from 30 Xinjiang Kazakh outpatients without antihypertensive drug therapy. They were randomly selected from our hypertension clinic from August 2012 to December 2012. The proliferated T lymphocytes were divided into control, telmisartan and TRAM-34 groups. After culturing for 0, 24, 48 h after corresponding treatments, the patch-clamp technique was employed to record the electrophysiological changes of IKCa1 potassium channel of T lymphocytes.
  
  
  RESULTS
  Under different treatment conditions, the IKCa1 potassium channel showed different electrophysiological changes. Pairwise comparison was made among the groups on the same time. For the telmisartan group, IKCa1 potassium channel peak current, peak current density of intervention 24 h and 48 h were significantly reduced compared with the control group (24 h:(835 ± 117)vs(1 471 ± 255) pA, (213 ± 61) vs (388 ± 129) pA/pF; 48 h:(631 ± 142) vs (1 555 ± 383) pA, (155 ± 54) vs (388 ± 114) pA/pF, all P < 0.01) . And the blocking rates of 0 h, 24 h and 48 h of telmisartan on IKCa1 potassium channel were 6.8%, 45.1% and 60.1% respectively.
  
  
  CONCLUSIONS
  Telmisartan can block the IKCa1 potassium channel of T lymphocytes in peripheral blood of hypertensive patients in Xinjiang Kazakh. It suggests that telmisartan may play an anti-inflammatory effect by blocking the IKCa1 potassium channels of T lymphocyte activation.
authors.affiliation: Department of Cardiology, First Teaching Hospital, Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Qiubing
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Email: zymdxx@163.com.
authors.forename: Yuanming
authors.initials: Y
authors.lastname: Zhang
authors.forename: Lufeng
authors.initials: L
authors.lastname: Cheng
authors.forename: Qingyan
authors.initials: Q
authors.lastname: Yuan
authors.forename: Guiming
authors.initials: G
authors.lastname: Zhang
authors.forename: Fang
authors.initials: F
authors.lastname: Gou
mesh_terms: D001562:Benzimidazoles / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000208:ethnology / Q000503:physiopathology*; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels / Q000187:drug effects*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000166:cytology; D000077333:Telmisartan
chemical_list: D001562:Benzimidazoles; D001565:Benzoates; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; D000077333:Telmisartan